| Literature DB >> 23815678 |
Philip C Gach1, Peter J Attayek, Gabriela Herrera, Jen Jen Yeh, Nancy L Allbritton.
Abstract
Described is the construction of a large array of releasable microstructures (micropallets) along with screening and isolation protocols for sorting rare, approximately 1 in 10,000, cancer stem cells (CSCs) from a heterogeneous cell populationpan>. A 10.1 × 7.1 cm array of micropallets (50 × 50 × 75 μm structures and 25 μm micropallet gap) was fabricated onpan> a large glass substrate, providinpan>g an array of approximately 1.3 millionpan> releasable microstructures. Image analysis algorithms were developed to permit array screeninpan>g for identificationpan> of fluorescently labeled cells inpan> less than 15 minpan> usinpan>g an epifluorescent wide-field microscope with a computer conpan>trolled translationpan>al stage. Device operationpan> was tested by culturinpan>g HeLa cells transfected with green fluorescent protein (GFP) admixed with wild-type HeLa cells at ratios of 1:10(4) to 1:10(6) on the array followed by screening to identify flourescent cells. Micropallets containing cells of interest were then selectively released by a focused laser pulse and collected on a numbered poly(dimethylsiloxane) (PDMS) substrate with high viability. A direct comparison of this technology with fluorescence-activated cell sorting (FACS) demonstrated that micropallet arrays offered enhanced post sorting purity (100%), yield (100%), and viability (94-100%) for rare cell isolation. As a demonstration of the technology's value, pancreatic tumor cells from Panc-1 cell lines and patient-derived xenografts were screened for the presence of CD24, CD44, and CD326: surface markers of pancreatic CSCs. Following cell isolation and culture, 63 ± 23% of the isolated Panc-1 cells and 35% of sorted human xenograft cells formed tumor spheroids retaining high expression levels of CD24, CD44, and CD326. The ability to isolate rare cells from relatively small sample sizes will facilitate our understanding of cell biology and the development of new therapeutic strategies.Entities:
Mesh:
Year: 2013 PMID: 23815678 PMCID: PMC3754897 DOI: 10.1021/ac401165s
Source DB: PubMed Journal: Anal Chem ISSN: 0003-2700 Impact factor: 6.986